Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lionel Ades

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Nature Communications|May 26, 2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemiaJacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2020
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Mathilde Ruggiu, Bruno Cassinat, Jean-Jacques Kiladjian, et al.
Haematologica|May 26, 2018
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)Ramy Rahmé, Lionel Ades, Xavier Thomas, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|March 25, 2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cellsHiba El Hajj, Zeina Dassouki, Caroline Berthier, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
British Journal of Haematology|November 24, 2018
Exome analysis of treatment-related AML after APL suggests secondary evolutionTianjiao Wang, Meagan A Jacoby, Eric J Duncavage, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Leukemia Research|June 24, 2016
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature reviewEric Grignano, Arsene Mekinian, Thorsten Braun, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Nature Communications|May 26, 2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemiaJacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2020
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Mathilde Ruggiu, Bruno Cassinat, Jean-Jacques Kiladjian, et al.
Haematologica|May 26, 2018
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)Ramy Rahmé, Lionel Ades, Xavier Thomas, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|March 25, 2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cellsHiba El Hajj, Zeina Dassouki, Caroline Berthier, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
British Journal of Haematology|November 24, 2018
Exome analysis of treatment-related AML after APL suggests secondary evolutionTianjiao Wang, Meagan A Jacoby, Eric J Duncavage, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Leukemia Research|June 24, 2016
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature reviewEric Grignano, Arsene Mekinian, Thorsten Braun, et al.
Pageof 8